Amplification of the bromodomain-containing protein 4 gene in ovarian high-grade serous carcinoma is associated with worse prognosis and survival.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Molecular and clinical oncology

• Publication date

  2015-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/MCO.2015.622PMID 26807235PMCID PMC4667564
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

  2015cited by this paper
• Histo‐genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non‐BRCAness high grade ovarian carcinoma

  2015cited by this paper
• Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia

  2014cited by this paper
• The mechanisms behind the therapeutic activity of BET bromodomain inhibition.

  2014cited by this paper
• Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation

  2013cited by this paper
• Selective inhibition of tumor oncogenes by disruption of super-enhancers.

  2013cited by this paper
• Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

  2013cited by this paper
• Targeting MYCN in neuroblastoma by BET bromodomain inhibition.

  2013cited by this paper
• Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer

  2013cited by this paper
• The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

  2012cited by this paper
• Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.

  2012cited by this paper
• Targeting MYC dependence in cancer by inhibiting BET bromodomains

  2011cited by this paper
• RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

  2011cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

  2011cited by this paper
• BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

  2011cited by this paper
• The biology of ovarian cancer: new opportunities for translation

  2009cited by this paper
• BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

  2005cited by this paper

• Proteogenomic profiling of soft tissue leiomyosarcoma reveals distinct molecular subtypes with divergent outcomes and therapeutic vulnerabilities

  2025cites this paper
• Anticancer Effects of BRD4 Inhibitor in Epithelial Ovarian Cancer

  2024cites this paper
• The Prognostic Role of BRD4 Expression in High-Grade Serous Ovarian Cancer

  2024cites this paper
• Recurrent Somatic Copy Number Alterations and Their Association with Oncogene Expression Levels in High-Grade Ovarian Serous Carcinoma

  2023cites this paper
• Increased expression of BRD4 isoforms long (BRD4-L) and short (BRD4-S) promotes chemotherapy resistance in high-grade serous ovarian carcinoma

  2023cites this paper
• Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells

  2023cites this paper
• Prognostic role of overexpressed Bromodomain and extra-terminal family in ovarian cancer

  2022cites this paper
• Design, synthesis and anti-ovarian cancer activities of thieno[2,3-d]pyrimidine based chimeric BRD4 inhibitor/nitric oxide-donator.

  2022cites this paper
• Exploiting epigenetic dependencies in ovarian cancer therapy

  2021cites this paper
• Clinical perspectives of BET inhibition in ovarian cancer

  2021cites this paper
• The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis

  2021influential citation
• CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes

  2020cites this paper
• Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma

  2020cites this paper
• Therapeutic Inducers of Apoptosis in Ovarian Cancer

  2019influential citation
• BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors

  2018cites this paper
• The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.

  2018cites this paper
• IDENTIFYING MOLECULAR TARGETS AND VALIDATING NOVEL THERAPIES FOR OVARIAN CANCER

  2018cites this paper
• Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells

  2018cites this paper
• Amplification of the NSD3-BRD4-CHD8 pathway in pelvic high-grade serous carcinomas of tubo-ovarian and endometrial origin.

  2017cites this paper